The Punjab and Haryana High Court has remanded a major tax litigation case involving Nectar Lifesciences back to the Appellate Authority. The decision reopens potential liabilities of Rs 95.56 crore that were previously under dispute, impacting the company's financial outlook until the appellate process concludes.
Nectar Lifesciences Tax Case Remanded for Fresh Review
High Court Remands Tax Matter | Potential Rs 95.56 Crore Exposure
Reader Takeaway: Court orders fresh review of tax dispute, re-opening previously dropped demands of Rs 89.32 crore for the firm.
What just happened
The Hon’ble High Court of Punjab and Haryana has issued an order dated September 24, 2026, regarding a tax litigation involving the Principal Commissioner of CGST, Ludhiana. The court has remanded the entire matter back to the Appellate Authority for fresh consideration, effectively pausing the finality of a previous order dated May 27, 2025.
Why this matters
This legal development re-introduces uncertainty regarding a total tax exposure of approximately Rs 95.56 crore. The company must now undergo a fresh review process, where a previously dropped demand of Rs 89.32 crore (including interest and penalties) and a separate remanded demand of Rs 6.24 crore will be re-examined by the Appellate Authority.
The backstory
In May 2025, the Commissioner (Appeal) had provided relief to Nectar Lifesciences by dropping the Rs 89.32 crore demand and quashing personal penalties levied against key management, including the Chairman and Managing Director, Mr. Sanjiv Goyal. The current High Court order disrupts this resolution and requires the Appellate Authority to adjudicate the claims once again.
What changes now
The legal status of the tax liability has reverted to a pending state. While the final liability remains unascertainable, the company is preparing for further scrutiny. Management has explicitly stated that if the upcoming Appellate Authority decision proves unfavorable, the company retains the right to escalate the matter to the Hon’ble Tribunal for further legal remedy.
Risks to watch
Investors should monitor the timeline for the new Appellate Authority hearings. Any adverse order could impact the company's cash flow or require provisions in future financial statements. Furthermore, the re-adjudication of personal penalties against leadership may also be a point of concern for governance-focused shareholders.